Englebert Financial Advisers LLC Makes New $903,000 Investment in Merck & Co., Inc. $MRK

Englebert Financial Advisers LLC purchased a new position in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 8,583 shares of the company’s stock, valued at approximately $903,000. Merck & Co., Inc. makes up about 1.0% of Englebert Financial Advisers LLC’s holdings, making the stock its 19th biggest holding.

Other hedge funds have also recently added to or reduced their stakes in the company. United Financial Planning Group LLC acquired a new position in Merck & Co., Inc. in the third quarter worth approximately $31,000. Wealth Watch Advisors INC acquired a new position in Merck & Co., Inc. in the third quarter worth approximately $34,000. Dunhill Financial LLC grew its position in Merck & Co., Inc. by 83.0% in the third quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock worth $35,000 after buying an additional 190 shares during the last quarter. Silicon Valley Capital Partners grew its position in Merck & Co., Inc. by 160.5% in the third quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock worth $35,000 after buying an additional 260 shares during the last quarter. Finally, Valued Wealth Advisors LLC grew its position in Merck & Co., Inc. by 26.9% in the fourth quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock worth $47,000 after buying an additional 94 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on MRK shares. JPMorgan Chase & Co. lifted their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. Cantor Fitzgerald lifted their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Citigroup started coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of Merck & Co., Inc. in a research report on Friday, May 1st. Finally, Guggenheim lifted their price target on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Trading Up 0.1%

Merck & Co., Inc. stock opened at $111.47 on Tuesday. The company has a 50 day moving average price of $116.69 and a 200 day moving average price of $108.65. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The firm has a market capitalization of $275.32 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 2.51 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the business posted $2.22 EPS. The company’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts forecast that Merck & Co., Inc. will post 5.16 EPS for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.